Search

everythinglearnresearchcommunity

for

Search:↓

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

Low-level laser therapy (LLLT) stimulates hair growth but current devices are expensive. A proposed non-profit project aims to create affordable, 3D-printed LLLT devices and collect data on their effectiveness.

A user had a disappointing dermatologist appointment where they were denied prescriptions for Dutasteride and oral Minoxidil for hair loss and were only offered a hair transplant referral. Other users sympathized, discussed self-medication, and suggested consulting a transplant doctor for up-to-date treatments.

A user started working with a leading hair cloning lab to address their hair loss. They have a computer science background and will assist with data science.

The conversation discusses potential hair loss treatments, including hair cloning, setipiprant, and topical finasteride, questioning their availability and effectiveness as permanent cures. The user is inquiring about the release dates and efficacy of these treatments.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

RU58841's potential side effects, particularly heart palpitations, are debated, with some attributing them to contamination with minoxidil. Users report mixed experiences, with some seeing no side effects and others cautioning about the lack of reliable data on RU58841's safety.

Whether Finasteride can keep alive the hair gained by Minoxidil after quitting it, and why beard hairs are not as susceptible to miniaturization. It is suggested that scalp hair may be dependent on Minoxidil and that DHT could be countered with Finasteride to some extent, but there is no definitive data proving this.

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

An 18-year-old decided to start taking finasteride for hair loss, justifying it by stating that finasteride is the most effective treatment available and that the risk of side effects is low, with clinical trials showing it stops hair loss in 80% of men. The user encourages others not to be deterred by negative forum posts and to consider their own experience and clinical data.

A 45-year-old male experienced significant hair regrowth and thicker eyebrows and eyelashes after five months of using oral finasteride (1.2mg) and minoxidil (3mg), despite initial side effects. He noticed improvements within the first month and reported minimal shedding, with the treatment being more effective than topical solutions.

The user shared their successful hair regrowth journey using minoxidil 5% twice daily and weekly microneedling. Other users suggested adding finasteride to maintain gains long-term.

The user has been using finasteride, minoxidil, and Nizoral for 9 months with little progress in hair regrowth and is considering switching to dutasteride. They experience daily scalp pain and anxiety, and are exploring other treatments like Head & Shoulders and consulting a dermatologist.

The conversation is about the delay in the release of GT20029 phase 2 results by Kintor. It also mentions Minoxidil, finasteride, and RU58841 as treatments for hair loss.

User considers trying RU58841 for hair loss and asks for advice on its effectiveness and application. Responses vary, with some reporting positive results and others warning about potential risks or lack of change.

The conversation discusses hair regrowth and miniaturization, with the user transitioning to oral dutasteride and oral minoxidil, and occasionally using topical minoxidil. The user observes baby hairs near the hairline but less on the scalp, indicating possible regrowth and shedding.

A 27-year-old male shared his 7-month hair regrowth progress using finasteride, keto shampoo, rosemary oil, and both oral and topical minoxidil. He experienced initial shedding but is pleased with the results and plans to continue the treatments.

A 21-year-old has been using 1mg finasteride and 2.5% minoxidil for 9 months with some improvement in hair density. They plan to add collagen, 1% ketoconazole shampoo, and biweekly microneedling to their routine.

Combining finasteride and dutasteride may enhance hair regrowth by targeting different enzymes, with positive results reported. Minoxidil, both oral and topical, is also used to improve effectiveness.

The user saw significant hair regrowth after using rosemary-castor oil, scalp massages, a derma roller, biotin shampoo, minoxidil-finasteride spray, and a PRP injection. They plan to continue this routine.

The conversation discusses GT20029 as a potential cure for hair loss and includes information on specific treatments used. Minoxidil, finasteride, and RU58841 are mentioned as related treatments.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

Vitamins and minerals like vitamin E, zinc, and iron may aid hair growth, especially in cases of deficiency. Pumpkin seed oil, saw palmetto, horsetail, and AminoMar show some promise for improving hair health and count.

Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.

The user has been using oral minoxidil, dutasteride, RU58841, and other treatments for hair loss over nine months, seeing some improvement in hair thickness and crown volume but continued thinning at the hairline. They plan to continue treatment for another nine months despite being sensitive to DHT fluctuations and are considering increasing dosages or other options like a hair transplant.

Hair loss treatments like Minoxidil, finasteride, and potential mRNA therapies are discussed. There is skepticism about targeting specific genes due to the complex genetic nature of hair loss.

A person shared their hair transplant experience at Diamond Hair Clinic, discussing the process, costs, and satisfaction with the results. They used Minoxidil, Duasteride, and vitamins for maintenance post-surgery.

A person had a hair transplant at Diamond Hair Clinic with Dr. Mehmet Demircioglu using the Sapphire FUE method with 4500 grafts. They are using Duasteride, oral and topical Minoxidil, and vitamins for recovery and hair growth.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.